Literature DB >> 7587844

Serum sialic acid concentration and coronary heart disease in NIDDM.

J C Pickup1, M B Mattock, M A Crook, G D Chusney, D Burt, A P Fitzgerald.   

Abstract

OBJECTIVE--To examine the association between serum sialic acid concentrations and coronary heart disease (CHD) in a cross-sectional study of non-insulin-dependent diabetes mellitus (NIDDM). RESEARCH DESIGN AND METHODS--NIDDM patients (n = 145) attending a diabetic clinic were studied. CHD status was assessed by questionnaire and electrocardiogram coding, and potential risk factor assessment included measurement of fasting serum lipid and lipoprotein concentrations, blood pressure, and urinary albumin excretion rate (AER). RESULTS--Male NIDDM patients with CHD had a higher serum sialic acid level than those without CHD: 2.56 (2.24, 2.72) mmol/l vs. 2.24 (2.18, 2.30) mmol/l, P = 0.01, mean (95% confidence interval). They were also older, had a longer duration of diabetes, had a higher AER, had higher total triglyceride, very-low-density lipoprotein triglyceride and cholesterol, and lipoprotein(a) concentrations, and had a lower apolipoprotein A1 concentration. In an age adjusted multiple lipoprotein(a), hypercholesterolemia, and hypertension were associated with CHD. In women, only hypertension treatment was associated with CHD. CONCLUSIONS--There is a strong univariate association between elevated serum sialic acid and CHD in men (but not women) with NIDDM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587844     DOI: 10.2337/diacare.18.8.1100

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  Significance of serum and urine neuraminidase activity and serum and urine level of sialic acid in diabetic nephropathy.

Authors:  Jamshid Roozbeh; Ahmad Merat; Farahnaz Bodagkhan; Raha Afshariani; Hooman Yarmohammadi
Journal:  Int Urol Nephrol       Date:  2011-01-05       Impact factor: 2.370

2.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

Authors:  J C Pickup; M B Mattock; G D Chusney; D Burt
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

3.  Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort.

Authors:  A S Wierzbicki; S Nishtar; P J Lumb; M Lambert-Hammill; C N Turner; M A Crook; M S Marber; J Gill
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

Review 4.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

Review 5.  Sialic acids in human health and disease.

Authors:  Ajit Varki
Journal:  Trends Mol Med       Date:  2008-07-06       Impact factor: 11.951

6.  Total and lipid bound sialic acid levels in patients with polycystic ovary syndrome.

Authors:  Ali Ozcan; Aykan Yücel; Volkan Noyan; Nevin Sağsöz; Osman Cağlayan
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-06-01

7.  Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients.

Authors:  Rooh Ullah Khan; Mohammad Bashir
Journal:  Nutr J       Date:  2015-01-26       Impact factor: 3.271

8.  Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS).

Authors:  S S Soedamah-Muthu; N Chaturvedi; J C Pickup; J H Fuller
Journal:  Diabetologia       Date:  2008-01-09       Impact factor: 10.122

Review 9.  Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside.

Authors:  Alexandre Mezentsev; Evgeny Bezsonov; Dmitry Kashirskikh; Mirza S Baig; Ali H Eid; Alexander Orekhov
Journal:  Biomedicines       Date:  2021-05-25

10.  Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype.

Authors:  Irene Vinagre; José Luis Sánchez-Quesada; Juan Sánchez-Hernández; David Santos; Jordi Ordoñez-Llanos; Alberto De Leiva; Antonio Pérez
Journal:  Cardiovasc Diabetol       Date:  2014-02-04       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.